The first and only FDA-approved pill proven to increase a woman’s sex drive.

Uses for flibanserin
Take-Home Points
Why is this medication prescribed?
What does it ‘treat’?

For a diagnosis, HSDD could not be due to the physiological effects of a substance or a general medical condition. Estimates of the prevalence of sexual desire problems vary widely depending on the criteria used – from 3% to 31% in one study. Others suggest up to 43% of women may experience low sexual desire. However, there is fierce debate about the definition of disorders of sexual desire, with HSDD described as a “highly controversial diagnostic construct”. The newer DSM-5, published in May 2013, combined features of HSDD and another condition known as female sexual arousal disorder, to form a new condition, female sexual interest/arousal disorder (FSIAD). This has stricter diagnostic criteria and as yet unknown prevalence. Originally trialled as an antidepressant, flibanserin found new life as a treatment for low sexual desire in women. After being rejected for approval by the FDA in 2010, developers Boehringer Ingelheim transferred the rights to Sprout Pharmaceuticals, which finally and controversially secured FDA approval in August 2015. Flibanserin modulates neurotransmitters in the brain, increasing levels of dopamine and norepinephrine and decreasing serotonin. As dopamine and norepinephrine promote sexual arousal, and serotonin reduces sexual arousal, flibanserin may increase libido by improving the balance between these neurotransmitter systems. The US FDA approval process was mired in controversy, particularly in relation to the active role of Sprout Pharmaceuticals in lobbying. It funded a high-profile public advocacy campaign called Even the Score, which misleadingly claimed the drug was initially rejected because of FDA sexism.

Uses for flibanserin

renal dosing

This has stricter diagnostic criteria and as yet unknown prevalence. Originally trialled as an antidepressant, flibanserin found new life as a treatment for low sexual desire in women. After being rejected for approval by the FDA in 2010, developers Boehringer Ingelheim transferred the rights to Sprout Pharmaceuticals, which finally and controversially secured FDA approval in August 2015. Flibanserin modulates neurotransmitters in the brain, increasing levels of dopamine and norepinephrine and decreasing serotonin. As dopamine and norepinephrine promote sexual arousal, and serotonin reduces sexual arousal, flibanserin may increase libido by improving the balance between these neurotransmitter systems.

generalized hypoactive sexual desire disorder, acquired

The US FDA approval process was mired in controversy, particularly in relation to the active role of Sprout Pharmaceuticals in lobbying. It funded a high-profile public advocacy campaign called Even the Score, which misleadingly claimed the drug was initially rejected because of FDA sexism. Despite counter campaigns by scientists and doctors, the FDA scientific advisory committee voted 18 to six in favour of approving the drug, with the condition that risk-management options were put in place. The lovegra women committee members were concerned the drug had significant risks from side-effects, particularly if used off label or taken in combination with alcohol, and few benefits. The committee’s recommendation that the drug be approved therefore attracted widespread criticism that it allowed politics to trump clinical science. Despite counter campaigns by scientists and doctors, the FDA scientific advisory committee voted 18 to six in favour of approving the drug, with the condition that risk-management options were put in place. The lovegra women committee members were concerned the drug had significant risks from side-effects, particularly if used off label or taken in combination with alcohol, and few benefits. The committee’s recommendation that the drug be approved therefore attracted widespread criticism that it allowed politics to trump clinical science.

Product	Dosage	Quantity + Bonus	Price
Kamagra Oral Jelly	100mg	30 + 5 Sachets	136.20€ 129.71€
Cialis Original	20mg	34 + 2 Pills	183.99€ 175.23€
Levitra Generic	10mg	180 + 10 Pills	246.74€ 234.99€
Cialis Soft Tabs	20mg	10 Pills	39.03€ 37.17€
Cialis Generic	5mg	30 + 4 Pills	53.56€ 51.01€
Kamagra Effervescent Tablets	100 mg	42 + 7 Pills	122.97€ 117.11€
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€
Levitra Generic	10mg	120 + 10 Pills	178.59€ 170.09€
Levitra Original	20mg	8 Pills	65.05€ 61.95€
Levitra Generic	20mg	60 + 6 Pills	131.11€ 124.87€
Levitra Original	20mg	64 + 4 Pills	298.45€ 284.24€

Within hours of the FDA approval, Sprout Pharmaceuticals was acquired by Valeant for $US1 billion.

Take-Home Points

A rigorous meta-analysis showed that, on average, flibanserin led to one-half an additional sexually satisfying event per month. This is a less optimistic finding than the (still underwhelming) one extra sexually satisfying event per month frequently quoted by reports. Flibanserin is approved for prescription only in the US; it is not available in Australia. US doctors must be certified before prescribing it, and dispensing pharmacists must also complete training. In the first month it was available, Addyi (the brand name of flibanserin) was prescribed just 227 times, compared with more than half a million for Viagra in its first month.

A note about sex and gender

Doctors had prescribed the drug fewer than 4,000 times as of February this year. In the US, a one-month supply of flibanserin (one 100mg tablet per day, taken at bed time) costs between $US200 to $US830, depending on insurance coverage and means of acquisition. That’s a lot of money for an extra sexually satisfying experience every two months. ∙ Sexual desire is regulated not only by the sex hormones testosterone and estrogen, but also by the neurotransmitters dopamine and norepinephrine, which enhance sexual interest and desire, and serotonin, which inhibits sexual interest and desire. ∙ Brain circuits that connect the prefrontal cortex (PFC) with limbic pleasure centers theoretically mediate motivation, interest, and desire.

Dosage Forms & Strengths

These circuits are hypothesized to be the sites of inefficient information processing associated with sexual disorders that are characterized by reduced interest and desire. Flibanserin theoretically improves sexual functioning by enhancing downstream release of dopamine and norepinephrine while reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire. Brain circuits of motivation and pleasure include frontostriatal pathways and neuronal projections involving the insula, amygdala, hypothalamus, and ventral striatum.Reference Georgiadis and Kringelbach 1 – Reference Pfaus 4 These brain areas hypothetically process rewarding stimuli, including sex, food, and drugs of abuse, along with other pleasurable stimuli, including the “runner’s high” of jogging, certain social experiences, relationships, achievements, aesthetics, and intellectual pursuits.Reference Georgiadis and Kringelbach 1 Recent research suggests that these same brain circuits are also involved when patients experience a lack of interest in and desire for sex.Reference Woodard, Nowak, Balon, Tancer and Diamond 5 , Reference Arnow, Millheiser and Garrett 6 Studies also indicate that a new therapeutic agent, flibanserin, improves interest in and desire for sex by hypothetically targeting these circuits and causing the release of dopamine and norepinephrine while also reducing the release of serotonin.Reference Stahl, Sommer and Allers 7 – Reference Aubert, Gustison and Gardner 11 Various psychiatric disorders affect reward processing and are associated with the loss of interest and desire to pursue pleasurable activities because they are no longer engaging or rewarding. Reward processing is one of the key symptom domains in the modern “dimensional approach” to psychiatric disordersReference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 because abnormal reward processing hypothetically causes symptoms that can cut across a wide number of conditions, including major depressive disorder (MDD), schizophrenia, dementia, substance abuse, eating disorders, and sexual disorders.Reference Goto and Grace 14 Symptoms may include generalized anhedonia; reduced positive affect; and lack of energy, enthusiasm, happiness, and self-confidence.Reference Georgiadis and Kringelbach 1 , Reference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 Reward processing is sometimes very specific, and various disorders can selectively disrupt interest in and desire for a particular type of reward. One example of this is a condition of reduced interest in and desire for sexual activity, called variously hypoactive sexual desire disorder (HSDD) or female sexual interest and arousal disorder (FSIAD). Valeant set the price of Addyi at $US800 per month, leading to accusations of price gouging. Sales flagged as insurers refused to cover the drug. With its stock value plummeting, Valeant reportedly dismissed the drug’s entire sales team and said it planned to reintroduce the drug at a later date. The company may be waiting until the 18-month restriction on direct-to-consumer marketing is over. A recent review of studies – including five published and three unpublished randomised clinical trials involving 5,914 women – concluded the overall quality of the evidence for both efficacy and safety outcomes was very low. The published studies reported more favourable outcomes than unpublished studies. The authors’ attempts to gain further information from study leaders and sponsors were not successful.

Why is this medication prescribed?

15 Regardless of the disorder’s label, 15 , Reference Clayton, Goldfischer and Goldstein 16 if a woman suffers from prolonged loss of sexual desire that causes her distress and cannot be explained by problematic relationships, stressors, or medical conditions, then it is considered to be a disorder of reward processing for sex, and as such is hypothetically mediated by inefficient information processing in reward circuits.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Interest in and desire for sexual activity is the first phase of the human sexual response, followed by arousal, and then by orgasm (accompanied in men by ejaculation).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Disorders of orgasm and ejaculation have been recognized ever since the introduction of Prozac (fluoxetine) and the other selective serotonin reuptake inhibitors (SSRIs), which raise serotonin and commonly inhibit or delay orgasm/ejaculation.Reference Stahl 18 Disorders of arousal became well known with the introduction of Viagra (sildenafil citrate) and other nitric oxide synthase (NOS) inhibitors, which raise nitric oxide levels and enhance arousal, improving erections in men.Reference Stahl 18 Finally, disorders of interest in and desire for sex have also long been identified as a consequence of agents that enhance the release of serotonin (eg, SSRIs) or that block the release of dopamine (antipsychotics).Reference Stahl 3 , Reference Pfaus 4 , Reference Stahl 8 , Reference Stahl 18 However, until recently, primary disorders of interest in and desire for sex have not been well recognized.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Recent changes in diagnostic criteria for sexual disorders have arguably made it even more difficult to reach a primary diagnosis of loss of interest in and desire for sex. Side-effects include dizziness (11.4% of users), drowsiness (11.2%), nausea (10.4%), fatigue (9.2%), insomnia (4.9%) and dry mouth (2.4%). The most serious problems – low blood pressure and a resulting loss of consciousness – are amplified by concurrent alcohol use. Other serious adverse events were uncommon but flibanserin can’t be viewed as safe without further studies including a broader range of diverse women.

Summary: A daily, non-hormonal pill for premenopausal women with HSDD.
Key benefit: Modest increase in sexual desire and satisfying events for some.
Key risk: Potentially severe interactions with alcohol and many medications.
Management: Strict adherence to REMS, bedtime dosing, and no alcohol.
Patient profile: Premenopausal woman with distress from low desire, otherwise healthy.
Provider role: Certify, counsel, monitor, and manage expectations.
Place in therapy: One option among a comprehensive approach to sexual health.
Public health impact: Highlighted need for and challenges in female sexual medicine.
Future: Continued evaluation of real-world outcomes and safety profile.

The FDA approved flibanserin on condition it carry a black-box warning not to drink alcohol while taking the medication. The manufacturer is also required to undertake three additional studies to examine the side-effects among women using alcohol with the drug. Strangely, the evidence about alcohol interactions with flibanserin presented to the FDA included data on 25 healthy volunteers, of whom only two were women. Side-effects are lessened if taken cenforce 150 uk at night, but it has been reported about one out of every eight women will discontinue flibanserin because of adverse effects. A rigorous meta-analysis showed that, on average, flibanserin led to one-half an additional sexually satisfying event per month.

Parameter	Description	Typical Values
Absorption	Rapid, high bioavailability	~52%
Peak Plasma Levels	1-2 hours after dosing	~1.5 hours
Half-life	Duration of effect	11 hours
Metabolism	Hepatic via CYP3A4	Major route
Excretion	Mainly via urine	87% in urine

This is a less optimistic finding than the (still underwhelming) one extra sexually satisfying event per month frequently quoted by reports.

What does it ‘treat’?

Within hours of the FDA approval, Sprout Pharmaceuticals was acquired by Valeant for $US1 billion. Valeant set the price of Addyi at $US800 per month, leading to accusations of price gouging. Sales flagged as insurers refused to cover the drug. With its stock value plummeting, Valeant reportedly dismissed the drug’s entire sales team and said it planned to reintroduce the drug at a later date. The company may be waiting until the 18-month restriction on direct-to-consumer marketing is over.

hepatic dosing

A recent review of studies – including five published and three unpublished randomised clinical trials involving 5,914 women – concluded the overall quality of the evidence for both efficacy and safety outcomes was very low. The published studies reported more favourable outcomes than unpublished studies. The authors’ attempts to gain further information from study leaders and sponsors were not successful. Side-effects include dizziness (11.4% of users), drowsiness (11.2%), nausea (10.4%), fatigue (9.2%), insomnia (4.9%) and dry mouth (2.4%). The most serious problems – low blood pressure and a resulting loss of consciousness – are amplified by concurrent alcohol use.

Addyi (filbanserin)

Other serious adverse events were uncommon but flibanserin can’t be viewed as safe without further studies including a broader range of diverse women. The FDA approved flibanserin on condition it carry a black-box warning not to drink alcohol while taking the medication. The manufacturer is also required to undertake three additional studies to examine the side-effects among women using alcohol with the drug. Strangely, the evidence about alcohol interactions with flibanserin presented to the FDA included data on 25 healthy volunteers, of whom only two were women. Side-effects are lessened if taken cenforce 150 uk at night, but it has been reported about one out of every eight women will discontinue flibanserin because of adverse effects. Flibanserin is approved for prescription only in the US; it is not available in Australia.

Clinical trials excluded women with many comorbidities (e.g., unstable medical conditions).
Real-world effectiveness in broader populations may differ from trial results.
Patient satisfaction with treatment can vary widely.
Some women report significant improvement in sexual desire and distress.
Others discontinue due to side effects or lack of meaningful benefit.
Adherence to daily dosing is a challenge for some patients.
The bedtime dosing schedule is intended to mitigate side effects like dizziness.
Taking it with a high-fat meal can increase absorption and side effect risk.
Should be taken on an empty stomach, at least 2 hours after a high-fat meal.

US doctors must be certified before prescribing it, and dispensing pharmacists must also complete training. In the first month it was available, Addyi (the brand name of flibanserin) was prescribed just 227 times, compared with more than half a million for Viagra in its first month. Doctors had prescribed the drug fewer than 4,000 times as of February this year. In the US, a one-month supply of flibanserin (one 100mg tablet per day, taken at bed time) costs between $US200 to $US830, depending on insurance coverage and means of acquisition. That’s a lot of money for an extra sexually satisfying experience every two months. ∙ Sexual desire is regulated not only by the sex hormones testosterone and estrogen, but also by the neurotransmitters dopamine and norepinephrine, which enhance sexual interest and desire, and serotonin, which inhibits sexual interest and desire. ∙ Brain circuits that connect the prefrontal cortex (PFC) with limbic pleasure centers theoretically mediate motivation, interest, and desire. These circuits are hypothesized to be the sites of inefficient information processing associated with sexual disorders that are characterized by reduced interest and desire. Flibanserin theoretically improves sexual functioning by enhancing downstream release of dopamine and norepinephrine while reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire. Brain circuits of motivation and pleasure include frontostriatal pathways and neuronal projections involving the insula, amygdala, hypothalamus, and ventral striatum.Reference Georgiadis and Kringelbach 1 – Reference Pfaus 4 These brain areas hypothetically process rewarding stimuli, including sex, food, and drugs of abuse, along with other pleasurable stimuli, including the “runner’s high” of jogging, certain social experiences, relationships, achievements, aesthetics, and intellectual pursuits.Reference Georgiadis and Kringelbach 1 Recent research suggests that these same brain circuits are also involved when patients experience a lack of interest in and desire for sex.Reference Woodard, Nowak, Balon, Tancer and Diamond 5 , Reference Arnow, Millheiser and Garrett 6 Studies also indicate that a new therapeutic agent, flibanserin, improves interest in and desire for sex by hypothetically targeting these circuits and causing the release of dopamine and norepinephrine while also reducing the release of serotonin.Reference Stahl, Sommer and Allers 7 – Reference Aubert, Gustison and Gardner 11 Various psychiatric disorders affect reward processing and are associated with the loss of interest and desire to pursue pleasurable activities because they are no longer engaging or rewarding. Reward processing is one of the key symptom domains in the modern “dimensional approach” to psychiatric disordersReference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 because abnormal reward processing hypothetically causes symptoms that can cut across a wide number of conditions, including major depressive disorder (MDD), schizophrenia, dementia, substance abuse, eating disorders, and sexual disorders.Reference Goto and Grace 14 Symptoms may include generalized anhedonia; reduced positive affect; and lack of energy, enthusiasm, happiness, and self-confidence.Reference Georgiadis and Kringelbach 1 , Reference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 Reward processing is sometimes very specific, and various disorders can selectively disrupt interest in and desire for a particular type of reward. One example of this is a condition of reduced interest in and desire for sexual activity, called variously hypoactive sexual desire disorder (HSDD) or female sexual interest and arousal disorder (FSIAD). 15 Regardless of the disorder’s label, 15 , Reference Clayton, Goldfischer and Goldstein 16 if a woman suffers from prolonged loss of sexual desire that causes her distress and cannot be explained by problematic relationships, stressors, or medical conditions, then it is considered to be a disorder of reward processing for sex, and as such is hypothetically mediated by inefficient information processing in reward circuits.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Interest in and desire for sexual activity is the first phase of the human sexual response, followed by arousal, and then by orgasm (accompanied in men by ejaculation).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Disorders of orgasm and ejaculation have been recognized ever since the introduction of Prozac (fluoxetine) and the other selective serotonin reuptake inhibitors (SSRIs), which raise serotonin and commonly inhibit or delay orgasm/ejaculation.Reference Stahl 18 Disorders of arousal became well known with the introduction of Viagra (sildenafil citrate) and other nitric oxide synthase (NOS) inhibitors, which raise nitric oxide levels and enhance arousal, improving erections in men.Reference Stahl 18 Finally, disorders of interest in and desire for sex have also long been identified as a consequence of agents that enhance the release of serotonin (eg, SSRIs) or that block the release of dopamine (antipsychotics).Reference Stahl 3 , Reference Pfaus 4 , Reference Stahl 8 , Reference Stahl 18 However, until recently, primary disorders of interest in and desire for sex have not been well recognized.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Recent changes in diagnostic criteria for sexual disorders have arguably made it even more difficult to reach a primary diagnosis of loss of interest in and desire for sex.